Can Acalabrutinib treat gastric cancer?

Acalabrutinib (Acalabrutinib) is mainly used to treat B cell-related diseases, such as chronic lymphocytic leukemia (CLL). It is a BTK inhibitor that blocks the growth and proliferation of cancer cells by inhibiting the B cell signaling pathway.

However, acotinib is not an approved drug for the treatment of stomach cancer. Currently, treatment for gastric cancer usually includes surgical resection, chemotherapy, targeted therapy, and immunotherapy. The specific treatment plan depends on the type of tumor, course of the disease, and the overall condition of the patient.

Although acotinib has shown good efficacy in the treatment of some leukemias and lymphomas, its role in the treatment of gastric cancer has not been widely confirmed. Treatment of gastric cancer usually requires comprehensive consideration of the molecular characteristics of the tumor and the patient's pathological condition to develop a personalized treatment plan.

It is important to note that medical research and treatment options are constantly evolving, and new information and treatment advances may be available. If you or someone you know has stomach cancer or other diseases, it is recommended to consult a professional doctor for the latest diagnosis and treatment recommendations. Doctors can develop the most appropriate treatment plan based on the patient's specific circumstances, including medical history, pathological characteristics, and other factors.

Acotinib has been launched in China, but it has not yet been included in medical insurance. Since it has just been launched, it is still difficult for patients to purchase it domestically. They need to purchase acotinib through overseas channels. The cheaper ones abroad are mainly generic drugs, mainly Bangladeshi generic drugs. The price is around 6,000 to 7,000, and the ingredients of original drugs and generic drugs are basically the same.